Eribulin mesylate vs Utidelone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Tubulin / microtubules · full HR+/HER2- Metastatic Breast Cancer pipeline
Eribulin mesylate
Marketed by Eisai and partners
NCT00337103 · Phase 3 · completed
Study 301 was an open-label, randomized Phase 3 trial of eribulin vs capecitabine in 1,102 women with metastatic breast cancer previously treated with an anthracycline and a taxane. The co-primary endpoints were overall survival and progression-free survival. Neither was significant: OS HR 0.88 (95% CI 0.77 to 1.00, P = .056) and PFS HR 1.08 (95% CI 0.93 to 1.25, P = .30). The paper concludes eribulin was not shown to be superior on either endpoint, so the primary was missed. Source: the peer-reviewed paper (Kaufman et al., J Clin Oncol 2015).
Next expected readout: June 2027 · NCT06942234 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) of Eribulin Arm by tumor assessment : Time to disease progression (Baseline until date of recorded disease progression or death, or up to 2 years); Progression-Free Survival (PFS) of Vinorelbine Arm by tumor assessment: Time to disease progression (Baseline until date of recorded disease progression or death, or up to 2 years); Maximum observed plasma concentration (Cmax) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Time at which the highest drug concentration occurs (tmax) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Area under the plasma concentration-time curve (AUC) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Terminal phase rate constant (lambda Z) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Terminal elimination phase half-life (t1/2) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Distribution volume at steady-state (Vss) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8); Total clearance (CL) of Eribulin Arm in a minimum of 15 subjects (Day 1 and Day 8): Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms (met)
Result source: NCT02225470
Utidelone
Marketed by Beijing Biostar Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05398861 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Eribulin mesylate | Utidelone |
|---|---|---|
| PFS, median | 4.1 vs 4.2vs CapecitabineNCT003371039 other results
| —Trial running · NCT05172518 |
| OS, median | 15.9 vs 14.5vs CapecitabineNCT003371035 other results
| —Trial running · NCT05172518 |
| ORR | 11% vs 11.5%vs CapecitabineNCT003371038 other results
| —Trial running · NCT05172518 |
| Clinical benefit rate | 57.1%bNCT01323530 | —Trial running · NCT05172518 |
PFS, median
- Eribulin mesylate
- 4.1 vs 4.2vs CapecitabineNCT00337103
9 other results
- 4.1 vs 4.2 NCT03051659
- 3.5 NCT01908101
- 3.6 NCT02481050
- 7.2 NCT01323530
- 6.2 NCT01827787
- 4 NCT01827787
- 4.1 NCT02061085
- 6.8 NCT01268150
- 2.8 vs 2.8 NCT02225470
- Utidelone
- —Trial running · NCT05172518
OS, median
- Eribulin mesylate
- 15.9 vs 14.5vs CapecitabineNCT00337103
5 other results
- 13.4 vs 12.5 NCT03051659
- 12.9 NCT02481050
- 20 NCT01827787
- 11.3 NCT01827787
- 15.7 NCT02581839
- Utidelone
- —Trial running · NCT05172518
ORR
- Eribulin mesylate
- 11% vs 11.5%vs CapecitabineNCT00337103
8 other results
- 12.3% NCT02481050
- 42.9% NCT01323530
- 35.6% NCT01827787
- 13.2% NCT01827787
- 28.6% NCT01268150
- 27% vs 34% NCT03051659
- 16% NCT01596751
- 11.1% NCT02581839
- Utidelone
- —Trial running · NCT05172518
Clinical benefit rate
- Eribulin mesylate
- 57.1%bNCT01323530
- Utidelone
- —Trial running · NCT05172518
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Utidelone: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Eribulin mesylate: 4 of 4 rows · Utidelone: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Eribulin mesylate |
|---|---|
| Dropout rate | n/a: no completion milestone1.4 mg/m^2a NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 35 more results12.9%1.4 mg/m^2 NCT01961544 · Phase 4 · registry result, not featured evidence 4.3% NCT03051659 · Phase 2 · registry result, not featured evidence · combination 0% NCT02581839 · Phase 2 · registry result, not featured evidence 13.2% NCT01908101 · Phase 2 · registry result, not featured evidence n/a: no completion milestone1.4 mg/m^2 NCT02481050 · Phase 2 · registry result, not featured evidence —Cohort A: Triple-negative Breast C NCT01401959 · Phase 2 · registry result, not featured evidence 1.9%Cohort A: Triple-negative Breast C NCT01401959 · Phase 2 · registry result, not featured evidence 0%Cohort B: ER/PR Positive/HER2-nega NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort C: HER2 Positive Breast Can NCT01401959 · Phase 2 · registry result, not featured evidence 0%Cohort C: HER2-positive Breast Can NCT01401959 · Phase 2 · registry result, not featured evidence — NCT01527487 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 1: HR+/HER2- NCT01827787 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2: TNBC NCT01827787 · Phase 2 · registry result, not featured evidence 15.1% NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy 50% NCT01268150 · Phase 2 · registry result, not featured evidence 8.6% NCT00965523 · Phase 2 · registry result, not featured evidence 0%1.4 mg/m2 NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 0%1.1 mg/m2 NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase II: Eribulin Combination w/ NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%600 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%600 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%400 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 20%2.0 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 33.3%1.6 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 50%1.4 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination —1.4 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 37.5%1.2 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 50%1.1 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 0%0.7 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 44.4% NCT01142661 · Phase na · registry result, not featured evidence |
| Discontinued due to AEs | 8.1%1.4 mg/m^2a NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 35 more results1%1.4 mg/m^2 NCT01961544 · Phase 4 · registry result, not featured evidence — NCT03051659 · Phase 2 · registry result, not featured evidence · combination — NCT02581839 · Phase 2 · registry result, not featured evidence — NCT01908101 · Phase 2 · registry result, not featured evidence 1.7%1.4 mg/m^2 NCT02481050 · Phase 2 · registry result, not featured evidence —Cohort A: Triple-negative Breast C NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort A: Triple-negative Breast C NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort B: ER/PR Positive/HER2-nega NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort C: HER2 Positive Breast Can NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort C: HER2-positive Breast Can NCT01401959 · Phase 2 · registry result, not featured evidence — NCT01527487 · Phase 2 · registry result, not featured evidence · combination —Cohort 1: HR+/HER2- NCT01827787 · Phase 2 · registry result, not featured evidence · combination —Cohort 2: TNBC NCT01827787 · Phase 2 · registry result, not featured evidence 15.1% NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy 5.4% NCT01268150 · Phase 2 · registry result, not featured evidence — NCT00965523 · Phase 2 · registry result, not featured evidence —1.4 mg/m2 NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination —1.1 mg/m2 NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination —Phase II: Eribulin Combination w/ NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination —1000 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —1000 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —600 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —600 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination —400 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 0%2.0 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 0%1.6 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 33.3%1.4 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination —1.4 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 25%1.2 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 0%1.1 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 0%0.7 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 22.2% NCT01142661 · Phase na · registry result, not featured evidence |
| Serious AEs | 17.5%1.4 mg/m^2a NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 35 more results19.8%1.4 mg/m^2 NCT01961544 · Phase 4 · registry result, not featured evidence 61.4% NCT03051659 · Phase 2 · registry result, not featured evidence · combination 33.3% NCT02581839 · Phase 2 · registry result, not featured evidence 3.4% NCT01908101 · Phase 2 · registry result, not featured evidence 24.1%1.4 mg/m^2 NCT02481050 · Phase 2 · registry result, not featured evidence 15.1%Cohort A: Triple-negative Breast C NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort A: Triple-negative Breast C NCT01401959 · Phase 2 · registry result, not featured evidence 2.4%Cohort B: ER/PR Positive/HER2-nega NCT01401959 · Phase 2 · registry result, not featured evidence 9.7%Cohort C: HER2 Positive Breast Can NCT01401959 · Phase 2 · registry result, not featured evidence —Cohort C: HER2-positive Breast Can NCT01401959 · Phase 2 · registry result, not featured evidence 7.4% NCT01527487 · Phase 2 · registry result, not featured evidence · combination 48.9%Cohort 1: HR+/HER2- NCT01827787 · Phase 2 · registry result, not featured evidence · combination 34.2%Cohort 2: TNBC NCT01827787 · Phase 2 · registry result, not featured evidence 20.8% NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy 30.4% NCT01268150 · Phase 2 · registry result, not featured evidence 17.3% NCT00965523 · Phase 2 · registry result, not featured evidence 33.3%1.4 mg/m2 NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 0%1.1 mg/m2 NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 13.2%Phase II: Eribulin Combination w/ NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 35.3%1000 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 50%1000 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 63.6%800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 33.3%800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 25%800 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 60%600 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 33.3%600 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 75%400 mg/day NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 20%2.0 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.6 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 66.7%1.4 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 23.8%1.4 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 25%1.2 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 50%1.1 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 66.7%0.7 mg/m^2 NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 77.8% NCT01142661 · Phase na · registry result, not featured evidence |
| Most frequent reported AEs | 1.4 mg/m^2a neutropenia 53.7% alopecia 34.6% leukopenia 31.4% NCT00337103 · Phase 3 · monotherapy · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 33 more results1.4 mg/m^2 neutropenia 91.1% alopecia 45.5% decreased appetite 40.6% NCT01961544 · Phase 4 · registry result, not featured evidence fatigue 88.6% nausea 56.8% alopecia 54.5% NCT03051659 · Phase 2 · registry result, not featured evidence · combination fatigue 88.9% anemia 66.7% constipation 66.7% NCT02581839 · Phase 2 · registry result, not featured evidence neutropenia 22% white blood cell decreased 6.8% fatigue 5.1% NCT01908101 · Phase 2 · registry result, not featured evidence 1.4 mg/m^2 fatigue 55.2% alopecia 50% neutropenia 43.1% NCT02481050 · Phase 2 · registry result, not featured evidence fatigue 63.5% neutrophil count decreased 50% peripheral sensory neuropathy 46.2% NCT01401959 · Phase 2 · registry result, not featured evidence fatigue 61.9% peripheral sensory neuropathy 59.5% leukopenia 54.8% NCT01401959 · Phase 2 · registry result, not featured evidence fatigue 74.2% neutrophil count decreased 54.8% anemia 51.6% NCT01401959 · Phase 2 · registry result, not featured evidence fatigue 74.1% nausea 61.1% alopecia 59.3% NCT01527487 · Phase 2 · registry result, not featured evidence · combination fatigue 64.4% alopecia 57.8% nausea 37.8% NCT01827787 · Phase 2 · registry result, not featured evidence · combination fatigue 65.8% nausea 44.7% alopecia 39.5% NCT01827787 · Phase 2 · registry result, not featured evidence alopecia 34% nausea 26.4% anorexia and bulimia syndrome 18.9% NCT02061085 · Phase 2 · registry result, not featured evidence · monotherapy alopecia 83.9% neutropenia 71.4% fatigue 64.3% NCT01268150 · Phase 2 · registry result, not featured evidence leukopenia 98.8% neutropenia 98.8% alopecia 58% NCT00965523 · Phase 2 · registry result, not featured evidence 1.4 mg/m2 nausea 100% alopecia 66.7% anorexia 66.7% NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 1.1 mg/m2 constipation 100% nausea 100% arthralgia 66.7% NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination dyspnea 47.4% back pain 31.6% pain in extremity 28.9% NCT01554371 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg/day fatigue 58.8% nausea 52.9% neutrophil count decreased 52.9% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg/day anorexia 66.7% nausea 66.7% alanine aminotransferase increased 33.3% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 800 mg/day fatigue 63.6% aspartate aminotransferase increased 45.5% alanine aminotransferase increased 36.4% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 800 mg/day rash maculo-papular 50% aspartate aminotransferase increased 33.3% fatigue 33.3% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 800 mg/day alanine aminotransferase increased 75% aspartate aminotransferase increased 75% anorexia 50% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 600 mg/day anorexia 60% fatigue 60% rash maculo-papular 60% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 600 mg/day fatigue 33.3% nausea 33.3% neutrophil count decreased 33.3% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 400 mg/day cough 75% dyspnea 50% fatigue 50% NCT01596751 · Phase 1/2 · registry result, not featured evidence · combination 2.0 mg/m^2 decreased appetite 100% nausea 80% alopecia 60% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 1.6 mg/m^2 lethargy 66.7% nausea 66.7% diarrhoea 50% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 1.4 mg/m^2 nausea 100% vomiting 100% neutropenia 83.3% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 1.4 mg/m^2 neutropenia 81% leukopenia 47.6% alopecia 35.7% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 1.2 mg/m^2 diarrhoea 75% nausea 50% headache 37.5% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 1.1 mg/m^2 lethargy 66.7% alopecia 50% diarrhoea 50% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination 0.7 mg/m^2 diarrhoea 66.7% dyspnoea 66.7% lethargy 66.7% NCT01323530 · Phase 1/2 · registry result, not featured evidence · combination fatigue 66.7% constipation 44.4% nausea 44.4% NCT01142661 · Phase na · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 35 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Eribulin mesylate
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 6 more results
show 1 more result
show 3 more results
show 6 more results
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eribulin mesylate's landscape · Utidelone's landscape